Shares of Stifel Financial were moving higher after it reported fourth-quarter adjusted earnings that beat Wall Street ...

Stifel upgraded C.H. Robinson (CHRW) to Buy from Hold with an unchanged price target of $113. The company reported “solid” Q4 results and the ...

Stifel chief executive Ron Kruszewski said surging markets have forced firms to be particularly choosy about which advisors ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

While total segment revenue declined 6.6% year-over-year due to weak truckload (TL) demand and lower rates, gross margins expanded. TL volumes fell 6.5% year-over-year, offset by a 2.5% increase in ...

Stifel Nicolaus analyst Brian Butler maintained a Buy rating on Greif Class A (GEF – Research Report) today and set a price target of $85.00.

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

After the market closed yesterday, Stifel published new coverage on Datadog. The firm downgraded its rating on the stock from ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

ST. LOUIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that its Board of Directors ...

Stifel's commentary also mentioned that C.H. Robinson has been considered a "show-me story," indicating that the market has been waiting for proof of the company's performance and strategy ...

Stifel expects DDOG’s challenges to hinder its revenue growth and profit margins this year. Noting that the company’s forward ...